# US 2009/0270431 A1 · Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270431 A1
- Document ID: US20090270431A1
- Status: Published application
- Kind: A1
- Application number: 12/083,571
- Filed: 2006-10-19
- Published: 2009-10-29
- Earliest claimed: 2005-10-19
- Assignees: University of Georgia Research Foundation, Inc.
- Inventors: David C.K. Chu; Jong Hyun Cho; Hyo-Joong Kim
- Web page: https://patentgrep.com/patent/US20090270431A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 31/12: Antivirals
- C07H 19/06: Pyrimidine radicals
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/16: Purine radicals
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A″ is H or OR1, with the proviso that when A′ is OR, A is H; and when A is OR2, A′ is H; X is C—R3 or N; Y is C—R3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R3 is H or C1-C3 alkyl; D is H or NHR2; E is absent or H; G is O or NHR2; J is N or C—R4; K is N or C—H; R4 is H, halogen (F, Cl, Br, I), CN, —C(═O)NH2, NH2, NO2, —C═C—H (cis or trans) or —C≡C—H; Ra is H or CH3; Each R1 is independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R2 is independently H, an acyl group, a C1-C20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.

## Claims

### Claim 1

A compound according to the structure I:
Where B is
A is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);
A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);
A″ is H or OR1,
with the proviso that when A′ is OR2, A is H; and when A is OR2, A′ is H;
X is C—R3 or N;
Y is C—R3 or N; preferably X or Y is N and X and Y are not both simultaneously N;
R3 is H or C1-C3 alkyl;
D is H or NHR2;
E is absent (when G is NHR2) or H;
G is O or NHR2;
J is N or C—R4;
K is N or C—H;
R4 is H, halogen (F, Cl, Br, I), CN, —C(═O)NH2, NH2, NO2, —C═C—H (cis or trans) or —C≡C—H;
Ra is H or CH3;
Each R1 is independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group;
Each R2 is independently H, an acyl group, a C1-C20 alkyl or ether group; and
pharmaceutically acceptable salts, solvates or polymorphs thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R1 and R2 are both H.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein A and A″ are OH and A′ is H.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein A or A′ is halogen.

### Claim 5 (depends on 1)

The compound according to claim 1 wherein A″ is H.

### Claim 6 (depends on 1)

The compound according to claim 1 wherein J is CR4.

### Claim 7 (depends on 1)

The compound according to claim 1 wherein G is NHR2.

### Claim 8 (depends on 1)

The compound according to claim 1 wherein K is N.

### Claim 9 (depends on 1)

The compound according to claim 1 wherein K is CH.

### Claim 10 (depends on 1)

The compound according to claim 1 wherein J is N, K is CH and G is O or NHR2.

### Claim 11 (depends on 1)

The compound according to claim 1 where D is NHR2.

### Claim 12 (depends on 1)

The compound according to claim 1 wherein B is

### Claim 13 (depends on 11)

The compound according to claim 11 wherein K is N.

### Claim 14 (depends on 11)

The compound according to claim 11 wherein K is CH.

### Claim 15 (depends on 11)

The compound according to claim 11 wherein J is C—R4.

### Claim 16 (depends on 12)

The compound according to claim 12 wherein G is O, E is H and D is NHR2.

### Claim 17 (depends on 12)

The compound according to claim 12 wherein G is NHR2, E is non-existent and D is H.

### Claim 18 (depends on 1)

The compound according to claim 1, wherein R4 is an acetylene group.

### Claim 19 (depends on 1)

The compound according to claim 1 wherein said compound is

### Claim 20 (depends on 1)

The compound according to claim 1 wherein R2 is H and R1 is an acyl group.

### Claim 21 (depends on 1)

The compound according to claim 1 wherein X and Y are both CH.

### Claim 22 (depends on 1)

The compound according to claim 1 wherein X or Y is N.

### Claim 23 (depends on 1)

The compound according to claim 1 which is

### Claim 24 (depends on 23)

The compound according to claim 23 wherein R1 and R2 are both H.

### Claim 25 (depends on 1)

A compound according to claim 1 wherein B is:

### Claim 26 (depends on 25)

The compound according to claim 25 wherein G is O and E is H.

### Claim 27 (depends on 25)

The compound according to claim 25 wherein Ra is H.

### Claim 28 (depends on 26)

The compound according to claim 26 wherein Ra is CH3.

### Claim 29 (depends on 25)

The compound according to claim 25 wherein G is NHR2, E is non-existent and Ra is H.

### Claim 30 (depends on 25)

The compound according to claim 25 wherein R1 and R2 are both H.

### Claim 31

A compound according to the structure:
Where R3 and R4 are the same or different and are independently H, a CORa group or a COORb group (preferably R3 and R4 are identical), or when R3 and R4 are both CORa groups, R3 and R4 together with the nitrogen to which they are attached may form a single or multi-ring system having two keto groups alpha to the nitrogen in the single or multi-ring system, with the proviso that both R3 and R4 are not simultaneously H;
Each Ra is the same or different and is independently a C1-C25 optionally substituted hydrocarbyl group (preferably each Ra is identical);
Each Rb is the same or different and is independently a C1-C25 optionally substituted hydrocarbyl group (preferably each Rb is identical); and
salts, solvates and polymorphs thereof.

### Claim at position 32

32-33. (canceled)

### Claim 34 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound according to claim 1 optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.

### Claim 35 (depends on 1)

A method of treating a viral infection whose causative agent is a virus selected from the group consisting of an Orthopox virus infection, severe acute respiratory syndrome virus-associated coronavirus (SARS virus), measles virus, human cytomegalovirus (HCMV), hepatitis B virus (HBV), hepatitis C virus (HCV), vaccinia virus, Herpes Simplex virus I (HSV-1), Herpes Simplex virus II (HSV-2), Varicella-Zoster virus (VZV), yellow fever virus, dengue virus, tacaribe virus, Rhinovirus (common cold), adenovirus, influenza A (flu A), influenza B (flu B), respiratory syncytial virus (RSV), parainfluenza virus (PIV), in a patient, comprising administering to said patient an effective amount of a compound or composition according to claim 1 to said patient.

### Claim at position 35

36-39. (canceled)

### Claim 40 (depends on 35)

The method according to claim 35 wherein said virus is a drug resistant virus.

### Claim 41 (depends on 1)

A method of reducing the likelihood of a viral infection in patient at risk for such an infection, said infection being caused by a virus selected from the group consisting of an Orthopox virus infection, severe acute respiratory syndrome virus-associated coronavirus (SARS virus), measles virus, human cytomegalovirus (HCMV), hepatitis B virus (HBV), hepatitis C virus (HCV), vaccinia virus, Herpes Simplex virus I (HSV-1), Herpes Simplex virus II (HSV-2), Varicella-Zoster virus (VZV), yellow fever virus, dengue virus, tacaribe virus, Rhinovirus (common cold), adenovirus, influenza A (flu A), influenza B (flu B), respiratory syncytial virus (RSV), parainfluenza virus (PIV), comprising administering to said patient at risk an effective amount of a compound or composition according to claim 1 to said patient.

### Claim 42

A method of synthesizing 3-deazaadenine comprising reacting a compound according to the structure:
where Y′ is Cl, Br, or I, preferably Cl
With an azide salt (preferably sodium or lithium azide) in the presence of ionic liquid to produce a tricyclic tetrazole compound according to the structure
and subjecting said tricyclic tetrazole compound to hydrogenation conditions to convert the azide group to an amino group to produce the compound

### Claim 43

(canceled)
